Discharge Medications After TIPS Procedure
For patients without prior hepatic encephalopathy (HE), rifaximin prophylaxis should be initiated at discharge to reduce the risk of post-TIPS HE, while lactulose is reserved for treatment of breakthrough episodes rather than routine prophylaxis. 1
Hepatic Encephalopathy Prophylaxis Strategy
For Patients WITHOUT Prior HE History
- Rifaximin prophylaxis is recommended based on a recent large RCT demonstrating significant reduction in first HE episodes post-TIPS (44.2% vs 59.1%, p = 0.05) 1
- This represents a shift from older evidence using uncovered stents that showed no benefit from prophylaxis 1
- The incidence of overt HE after TIPS ranges from 25-50%, making prophylaxis clinically meaningful 1
For Patients WITH Prior HE History
- Lactulose should be initiated at discharge as these patients are at substantially higher risk for post-TIPS HE 1
- Consider adding rifaximin immediately if the patient had recurrent HE episodes pre-TIPS 1
- Most studies excluded patients with recurrent overt HE, so this population requires particularly aggressive prophylaxis 1
Treatment Algorithm for Post-Discharge HE
First episode of overt HE post-TIPS:
- Initiate lactulose as first-line therapy 1
Subsequent episodes of overt HE:
- Add rifaximin to ongoing lactulose therapy 1
Refractory HE (≥3 unprovoked episodes requiring hospitalization in 3 months):
- Consider TIPS reduction/occlusion, which occurs in approximately 8% of recipients 1
Additional Risk Stratification for Discharge Planning
Patients at highest risk for post-TIPS HE requiring closer follow-up include those with: 1
- Advanced liver dysfunction (Child-Pugh Class C, MELD >18)
- Older age
- Elevated creatinine
- Hyponatremia
- Sarcopenia
Important Caveats
- The evidence for rifaximin prophylaxis is strongest in patients without prior HE 1
- Lactulose prophylaxis alone (without rifaximin) has not shown benefit in preventing first HE episodes in modern studies with covered stents 1
- Recent meta-analysis data suggests pharmacological prevention reduces HE incidence overall (OR 0.59), with rifaximin specifically showing benefit (OR 0.52) while lactulose monotherapy did not 2
- Patient and family counseling about HE manifestations should occur before discharge, particularly for those with poor social support 1